TGFB1 and neoplasm: On that early time point, tumor weights were already significantly reduced in mice treated with anti-GARP:TGF-β1 combined with anti-PD-1 by comparison to mice receiving the isotype control antibody (Fig. 5a and Supplementary Fig. 7a).